Risk of Second Malignant Neoplasms Among Long-term Survivors of Testicular Cancer

Travis, Lois B.; Curtis, Rochelle E.; Fraumeni, Joseph F.; Boice, John D.; Storm, Hans H.; Andersson, Michael; Hall, Per; Bergfeldt, Kjell; Holowaty, Eric J.; Clarke, E. Aileen; Leeuwen, Flora E. van; Kohler, Betsy A.; Pukkala, Eero; Wıklund, Tom; Stoter, G; Gospodarowicz, Mary K.; Sturgeon, J.

doi:10.1093/jnci/89.19.1429

Cited by 475 publications

(313 citation statements)

References 49 publications

Supporting

Mentioning

283

Contrasting

Unclassified

Order By: Relevance

“…Previous studies have shown that men with testicular cancer continue to be at significantly an elevated risk of second bladder cancer for more than two decades after initial diagnosis (Travis et al, 1997). These data corroborated this result and showed that, even 26 -35 years after testicular cancer diagnosed before the age of 40 years, the SIR was around 6.…”

Section: Discussionsupporting

confidence: 75%

“…The second approach investigated the pattern of risk after first tumours: asynchronous constant or decreasing relative risks may favour shared risk factors, whereas increasing risks with increasing lead time should point to treatment effects (Heard et al, 2005). There is an excellent literature on the development of bladder tumours after specific types of cancer, for example after prostate, oesophageal, testicular, cervical and lung tumours, and after lymphomas (Kaldor et al, 1987;Pettersson et al, 1990;Pathak Bjorge et al, 1995;Bokemeyer and Schmoll, 1995;Travis et al, 1995Travis et al, , 1997Levi et al, 1996Levi et al, , 1999Fisher et al, 1997;Teppo et al, 2001;Dores et al, 2002;Brennan et al, 2005;Heard et al, 2005;Liauw et al, 2006;Bostrom and Soloway, 2007;Chaturvedi et al, 2007;Kellen et al, 2007;Landgren et al, 2007;Muller et al, 2007;Chuang et al, 2008;Singh et al, 2008). The main advantage of this study was the simultaneous investigation of the most common types of cancer before bladder tumours using a uniform reference population.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Bladder cancer in cancer patients: population-based estimates from a large Swedish study

Bermejo

Sundquist²,

Hemminki

2009

Br J Cancer

View full text Add to dashboard Cite

BACKGROUND: This study quantified the risk of urinary bladder neoplasms in cancer patients taking into account the age at first diagnosis, the gender of the patients and the lead time between diagnoses. METHODS: We used standardised incidence ratios (SIRs) to compare the incidence of bladder tumours in 967 767 cancer patients with the incidence rate in the general Swedish population. A total of 3324 male and 1560 female patients developed bladder tumours at least 1 year after first cancer diagnosis. RESULTS: After bladder and renal pelvis cancers, the SIRs of bladder neoplasms were higher in female than in male patients. Men affected by lung, stomach and larynx tumours belonged to the population at high risk for bladder cancer. Treatment of breast, ovarian and cervical cancers seems to contribute to the subsequent development of bladder neoplasms. Long latencies (16 -25 years) were observed after testicular, cervical and endometrial cancers. Detection bias had an important role after prostate cancer. Chemotherapy with cyclophosphamide and cisplatin, and also radiotherapy, seem to increase the risk of subsequent neoplasms in the bladder. CONCLUSIONS: These population-based results may help urologists to assess the risk of bladder neoplasms in cancer survivors. Our data should guide ongoing studies that investigate the effectiveness of bladder cancer screening in cancer patients.

show abstract

Section: Discussionsupporting

confidence: 75%

Section: Discussionmentioning

confidence: 99%

Bladder cancer in cancer patients: population-based estimates from a large Swedish study

Bermejo

Sundquist²,

Hemminki

2009

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…5 For most sites, our findings are moderately in accordance with the results from literature. [2][3][4][5][6][7][11][12][13] Our results show that from 5366 patients diagnosed with a malignant primary epithelial ovarian tumor, 142 cases also manifested a concurrent endometrial malignancy (2.6%). Sheu et al report six cases from 421 ovarian cancer patients, who were also diagnosed with a synchronously endometrial cancer.…”

Section: Discussionmentioning

confidence: 99%

“…Genetic and reproductive factors predisposing to ovarian cancer may also contribute to the elevated risk of breast, colorectal neoplasms and possibly melanoma. 6,7 The objective of the present study was to determine the excess risk of a concurrent primary malignant tumor in women with malignant primary epithelial ovarian tumor.…”

mentioning

confidence: 99%

Increased risk of concurrent primary malignancies in patients diagnosed with a primary malignant epithelial ovarian tumor

et al. 2007

View full text Add to dashboard Cite

Ovarian cancer and second malignant neoplasms are found to occur rather frequently in the same patient. From a clinical perspective, it is important to have quantitative information on concurrent malignancies in the same year of diagnosis of the epithelial ovarian cancer. In this population-based study, we used data from the Netherlands Nationwide Network for Registry of histo-and cytopathology (PALGA) and the Netherlands Cancer Registry (NCR). Data of the ovarian cancer as well as data on previous or later cancers were obtained. Agespecific cancer rates from the NCR were used to calculate expected numbers of cancer. Between 1987 and 1993, histopathology reports were identified of 4577 patients with primary epithelial malignant or primary borderline malignant ovarian cancers and its longitudinal data. As the database may lack detailed information on histopathology, a recent sample of 789 patients diagnosed with ovarian cancer in 1996-2003 was comprehensively studied as well. In the eventual data analysis of 5366 patients, 244 cases (4.5%) of concurrent primary malignancy were reported in the same year that the malignant epithelial ovarian tumor had been diagnosed against 51 expected. The observed vs expected ratio was 4.8 and the 95% confidence interval (CI) (4.3-5.5). For cancer of the uterus/endometrium the observed vs expected ratio was 62.3 (95% CI 52.5-73.5). For skin, breast, colorectal, urinary bladder, renal and cervical cancer the ratio was also larger than unity. The elevated risk of concurrent cancer may lead to clinical screening protocols. The findings on endometrial cancer may prompt research on common etiologies and biomarkers.

show abstract

“…Two NMR samples were prepared for both the undamaged DNA and CP-GG DNA adduct, one in 5% D 2 O (40). The assignments were obtained initially from NOE connectivities and confirmed by analysis of 2D DQF-COSY (41) (2048 × 720 complex points, 9 ppm spectral width in both dimensions, 32 transients) and TOCSY data (2048 × 320 complex points, 9 ppm spectral width in both dimensions, 32 transients).…”

Section: Nmr Experimentsmentioning

confidence: 99%

Solution Structures of a DNA Dodecamer Duplex with and without a Cisplatin 1,2-d(GG) Intrastrand Cross-Link: Comparison with the Same DNA Duplex Containing an Oxaliplatin 1,2-d(GG) Intrastrand Cross-Link^,

et al. 2007

View full text Add to dashboard Cite

Proteins that discriminate between cisplatin-DNA adducts and oxaliplatin-DNA adducts are thought to be responsible for the differences in tumor range, toxicity, and mutagenicity of these two important chemotherapeutic agents. However, the structural basis for differential protein recognition of these adducts has not been determined and could be important for the design of more effective platinum anticancer agents. We have determined high-resolution NMR structures for cisplatin-GG and undamaged DNA dodecamers in the AGGC sequence context and have compared these structures with the oxaliplatin-GG structure in the same sequence context determined previously in our laboratory. This structural study allows the first direct comparison of cisplatin-GG DNA and oxaliplatin-GG DNA solution structures referenced to undamaged DNA in the same sequence context. Non-hydrogen atom rmsds of 0.81 and 1.21 were determined for the 15 lowest-energy structures for cisplatin-GG DNA and undamaged DNA, respectively, indicating good structural convergence. The theoretical NOESY spectra obtained by back-calculation from the final average structures showed excellent agreement with the experimental data, indicating that the final structures are consistent with the NMR data. Several significant conformational differences were observed between the cisplatin-GG adduct and the oxaliplatin-GG adduct, including buckle at the 5′ G6•C19 base pair, opening at the 3′ G7•C18 base pair, twist at the A5G6•T20C19 base pair step, slide, twist, and roll at the G6G7•C19C18 base pair step, slide at the G7C8•C18G17 base pair step, G6G7 dihedral angle, and overall bend angle. We hypothesize that these conformational differences may be related to the ability of various DNA repair proteins, DNA binding proteins, and DNA polymerases to discriminate between cisplatin-GG and oxaliplatin-GG adducts. † This work was supported by NIH Grant CA8440 (to S.G.C.) and NIEHS Grant P30ES10126 (to J.A.S.). ‡ Coordinates are available from the Protein Data Bank (PDB): 2NPW for the averaged structure of the CP-GG adduct and 2NQ0 for the family of the 15 best structures, 2NQ1 for the averaged structure of undamaged DNA in the AGGC sequence context, and 2NQ4 for the family of the 15 best structures.

show abstract

Risk of Second Malignant Neoplasms Among Long-term Survivors of Testicular Cancer

Cited by 475 publications

References 49 publications

Bladder cancer in cancer patients: population-based estimates from a large Swedish study

Bladder cancer in cancer patients: population-based estimates from a large Swedish study

Increased risk of concurrent primary malignancies in patients diagnosed with a primary malignant epithelial ovarian tumor

Solution Structures of a DNA Dodecamer Duplex with and without a Cisplatin 1,2-d(GG) Intrastrand Cross-Link: Comparison with the Same DNA Duplex Containing an Oxaliplatin 1,2-d(GG) Intrastrand Cross-Link^,

Contact Info

Product

Resources

About

Risk of Second Malignant Neoplasms Among Long-term Survivors of Testicular Cancer

Cited by 475 publications

References 49 publications

Bladder cancer in cancer patients: population-based estimates from a large Swedish study

Bladder cancer in cancer patients: population-based estimates from a large Swedish study

Increased risk of concurrent primary malignancies in patients diagnosed with a primary malignant epithelial ovarian tumor

Solution Structures of a DNA Dodecamer Duplex with and without a Cisplatin 1,2-d(GG) Intrastrand Cross-Link: Comparison with the Same DNA Duplex Containing an Oxaliplatin 1,2-d(GG) Intrastrand Cross-Link,

Contact Info

Product

Resources

About

Solution Structures of a DNA Dodecamer Duplex with and without a Cisplatin 1,2-d(GG) Intrastrand Cross-Link: Comparison with the Same DNA Duplex Containing an Oxaliplatin 1,2-d(GG) Intrastrand Cross-Link^,